Eleison Pharmaceuticals Inc. (ELSN)
Eleison Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2020 | 2019 |
|---|---|---|
| Revenue | 1 | 1.07 |
| Revenue Growth (YoY) | -6.25% | - |
| Gross Profit | 1 | 1.07 |
| Selling, General & Admin | 0.87 | 0.54 |
| Research & Development | 0.67 | 0.97 |
| Operating Expenses | 1.54 | 1.51 |
| Operating Income | -0.54 | -0.44 |
| Interest Expense / Income | 1.37 | 1.29 |
| Other Expense / Income | 3.9 | -0.01 |
| Pretax Income | -6.4 | -1.72 |
| Net Income | -5.8 | -1.72 |
| Preferred Dividends | -0.6 | - |
| Net Income Common | -6.4 | -1.72 |
| Gross Margin | 100.00% | 100.00% |
| Operating Margin | -54.02% | -41.26% |
| Profit Margin | -640.30% | -161.65% |
| Free Cash Flow Margin | -651.68% | -93.74% |
| EBITDA | -3.8 | -0.36 |
| EBITDA Margin | -379.83% | -33.64% |
| Depreciation & Amortization | 0.04 | 0.08 |
| EBIT | -3.84 | -0.43 |
| EBIT Margin | -383.86% | -40.78% |
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).